Biobullz, I think we should keep a long view, remember what is in the full pipeline, and that pipeline continues to grow, remember that continuation of ACT IV is not failure and no previous trial of Rintega has failed. Remember that Celldex for now has plenty of cash, and we may see some early results of Varli combo trials this year, and remember that Glemba's p3 breast cancer trial is in motion.
I think if ACT IV is stopped early for efficacy, consider it a gift, and yes, that could happen. But expect to wait for final results late this year. I expect the FDA to approve Rintega, Varli, and Glemba. I expect the shorts to have their way with Celldex until news changes their behavior. I expect Celldex to be a very successful biotech in the coming months and years, or until they are made an offer they can't refuse.
I remain long at this time, but have taken lots of profits along the way over many years, paid lots of bills, don't regret anything. Waiting for additional good trial results, and if it goes down further, I will be buying. JMHO
What percentage of the US voting public are socialist? When the fact that is Sanders is a socialist becomes the focus, do believe he will win enough electoral votes be win the office? I doubt the Dem party leaders will let him get so far in the process. Though I certainly hope they do.
Pissant, maybe you should start buying fish. Bears are getting rather full.
Pissant, this is a company with little to no revenue, of course it will see big sp swings, market and data driven.
Your crystal ball is no more clear than mine, and you only show up when the trend is down. Well we have had several significant trends to the upside as well, and I have paid a bunch of bills with those funds. So worry about yourself, I am doing fine, and Celldex will be fine as well. Enjoy your temporary short rant, your time being correct is limited, Celldex will have revenue in the future and you will move on to another small biotech with no revenue and claiming to always call it right after the fact. For now, enjoy your profits, and your ranting. When the trend changes again, maybe it will change your handle and you can claim to be long, again.
"I already told you at the end of 2015 that we were going to walk CLDX under $3.00 to 2.50 in March 2016."
You did, did you? You said that in 2015, and your first post was in Feb 2016? What a "side-winder".
7 posts | Last Activity: 42 seconds ago
Member since: Feb 8, 2016
He needs something to do while he awaits HRC's indictment, clearing the way for his beatdown in the general election as he runs on BHO's record.
Whipper, it's like the sibling that no one speaks of anymore, except during holidays at the dinner table.
Would be nice to see good news on TP10 one morning. With the way the market was previously reacting to its potential, that could get stirred up again. Maybe...
1champ, "okay but how were they valued much higher to begin with?"
The market was hoping for early approval on the Rintega/Avastin combo p2 trial in recurrent v3GBM. Data was vastly in favor of Rintega combo vs Avastin alone, but FDA said the trial was not powered enough to be a pivotal trial.
When the market came to realize they would have to wait for ACTIII data, thats when the share price started its precipitous drop, and the larger bio market sentiment in a political climate has not helped. Also, keep in mind that Celldex has seen very promising data from other trials in their pipeline, which should also be assessed proportionate value to the future sp. Varli alone is said to have a potential for multi billion annually in sales. Glemba for breast cancer is also in p3, and the p2 did look very promising. And so on, and so on, and so on.
Nov 24, 2015
"In a 73-patient Phase II trial of glioblastoma patients with the EGFRvIII mutation, 25% of those who received Rintega plus Roche's ($RHHBY) Avastin were alive after two years, while no patients who received only Avastin were alive. Rintega's advantages were further shown over endpoints such as overall survival, progression-free survival, objective response rate and need for steroids, Celldex added.
Celldex's chief medical officer, Thomas Davis, said in a statement that patients with the cancer face a "staggering diagnosis" and the new results "replicate what we have seen in earlier Rintega studies conducted in newly-diagnosed patients, supporting our belief that Rintega will be an important treatment option for all patients with EGFRvIII-positive glioblastoma.""
Think longer term, if you can, and consider the entire pipeline. Rintega is most likely to see approval, eventually, and likely to be combined with other therapy, maybe with Varli and others. JMHO